Despite few manageable side effects, the favorable outcomes on tumor response and quality of life of trametinib-based therapy in Lebanese pediatric LGG patients suggest that MEK inhibitors may be a feasible option in selected LMIC settings, when appropriate diagnostic and monitoring infrastructure is available.
BACKGROUND
MEK inhibition has demonstrated activity in pediatric low-grade gliomas (pLGGs) driven by BRAF rearrangements, but data on trametinib remain limited, regarding efficacy, short and long-term toxicities.
METHODS
We conducted a retrospective multicenter study of patients with BRAF-rearranged non NF1 pLGGs rec...
Céline Khouri, Amandine Bibollet, Y. Bouchoucha et al.· European Journal of Cancer· 0 citations
Vemurafenib showed efficacy in children with recurrent or progressive BRAFV600E-mutant brain tumors with acceptable toxicity, however, the rebound rate of 23% warrants further investigation.
T. Nicolaides, R. Hoogendijk, Marie Jaeger-Krause et al.· JCO Precision Oncology· 0 citations
Background and aim This retrospective cohort study aimed to characterize the real-world clinical outcomes and treatment-emergent adverse events (TEAEs) of anlotinib-containing regimens among pediatric patients with solid tumors treated at the Children’s Hospital of Zhejiang University School of Medicine from January 20...
Qiao Hua, Zhou Xia, Ya-Qing Gu et al.· Frontiers in Oncology· 0 citations
PURPOSE
Anaplastic lymphoma kinase (ALK) alterations occur in a range of rare malignancies; however, prospective evidence supporting alectinib beyond lung cancer remains limited. We evaluated the activity and safety of alectinib in patients with advanced ALK-altered solid tumors.
PATIENTS AND METHODS
In this open-lab...
H. Okuma, A. Arakawa, Akihiro Hirakawa et al.· Clinical Cancer Research· 0 citations
The use of comprehensive molecular profiling to identify patients most likely to benefit from immunotherapy and warrant validation in prospective clinical trials is supported, and encouraging clinical activity in selected CAYAs with solid tumors when guided by tumor-specific biomarkers is demonstrated.
Andy Huy-Dat Vu, M. Brizini, M. Brisson et al.· Cancer Research· 0 citations
PURPOSE
Selpercatinib, a highly selective oral RET inhibitor with CNS activity, has previously demonstrated durable responses and an acceptable safety profile in adults with RET-driven cancers. Consequently, the safety and efficacy of selpercatinib were investigated in pediatric/adolescent participants.
METHODS
LIBRE...
T. Laetsch, H. Kang, M. Casanova et al.· Journal of Clinical Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
